Neurostart Competitors

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.

Neurotrack is a cognitive care enablement platform that helps primary care teams detect, diagnose, and manage cognitive decline earlier. Founded on decades of neuroscience research, Neurotrack replaces outdated paper-based screeners with a fast, reliable digital assessment that fits into routine visits or can be self-administered by patients at home, before an appointment, or anywhere care happens. The result: providers gain the confidence to act on cognitive concerns rather than refer and wait, and patients get answers years sooner. Earlier detection also carries direct economic value. Under CMS's V28 risk adjustment model, accurate dementia diagnosis and documentation protect appropriate reimbursement, while earlier intervention reduces the avoidable hospitalizations and emergency utilization that drive costs in undiagnosed populations. With seamless integration into leading EMRs, including Epic, Neurotrack partners with health systems, health plans, and value-based care organizations to close the gap between the first signs of cognitive decline and a documented diagnosis with a care plan behind it.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.